Clinical trials: Nephrotic Syndrome in Children
Frequent Relapsing Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective than MMF in maintaining remission in children with frequent relapsing or steroid dependent nephrotic syndrome who have had one relapse while…
- Trial name
- RAMP (NCT02390362)
- Testing
- Rituximab, MMF
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Nationwide Children's Hospital
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT02592798
- Testing
- Abatacept, Normal Saline, D5W
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Nephrotic Syndrome
Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children
To determine the efficacy of tacrolimus in the management of NS(nephrotic syndrome) , the investigators designed this prospective study.
- Trial name
- NCT01162005
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD).
- Trial name
- NCT01113385
- Testing
- D-Galactose
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's National Research Institute